S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33

NRx Pharmaceuticals Stock Forecast, Price & News

-0.59 (-5.89 %)
(As of 09/24/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.03 million shs
Average Volume1.80 million shs
Market Capitalization$506.55 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NRXP News and Ratings via Email

Sign-up to receive the latest news and ratings for NRx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

About NRx Pharmaceuticals

NRX Pharmaceuticals, Inc. is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company recently announced a commercial partnership with Relief Therapeutics Holding AG for global commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure (the ""NRx COVID-19 Drug""). It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior the ""NRx Antidepressant Drug Regimen."" The company is headquartered in Wilmington, DE.


NRx Pharmaceuticals (NASDAQ:NRXP) Stock Price Down 3.8%
NRx Pharmaceuticals (NASDAQ:NRXP) Stock Price Down 3.8%
September 22, 2021 |  americanbankingnews.com
NRx Pharmaceuticals (NASDAQ:NRXP) Shares Gap Down to $11.58
NRx Pharmaceuticals (NASDAQ:NRXP) Shares Gap Down to $11.58
September 16, 2021 |  americanbankingnews.com
NRx Pharmaceuticals (NASDAQ:NRXP) Trading Down 6.2%
NRx Pharmaceuticals (NASDAQ:NRXP) Trading Down 6.2%
September 15, 2021 |  americanbankingnews.com
NRx Pharmaceuticals (NASDAQ:NRXP) Shares Gap Up to $10.98
NRx Pharmaceuticals (NASDAQ:NRXP) Shares Gap Up to $10.98
September 14, 2021 |  americanbankingnews.com
NRx Pharmaceuticals (NASDAQ:NRXP) Trading Down 3.3%
NRx Pharmaceuticals (NASDAQ:NRXP) Trading Down 3.3%
September 9, 2021 |  americanbankingnews.com
NRx Pharmaceuticals (NASDAQ:NRXP) Shares Gap Down to $14.91
NRx Pharmaceuticals (NASDAQ:NRXP) Shares Gap Down to $14.91
September 7, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.17 out of 5 stars

Medical Sector

1170th out of 1,352 stocks

Pharmaceutical Preparations Industry

569th out of 666 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

NRx Pharmaceuticals (NASDAQ:NRXP) Frequently Asked Questions

What stocks does MarketBeat like better than NRx Pharmaceuticals?

Wall Street analysts have given NRx Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but NRx Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting NRx Pharmaceuticals?

NRx Pharmaceuticals saw a increase in short interest in August. As of August 31st, there was short interest totaling 2,260,000 shares, an increase of 119.4% from the August 15th total of 1,030,000 shares. Based on an average daily trading volume, of 4,720,000 shares, the days-to-cover ratio is currently 0.5 days. Approximately 12.1% of the company's stock are sold short.
View NRx Pharmaceuticals' Short Interest

When is NRx Pharmaceuticals' next earnings date?

NRx Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 15th 2021.
View our earnings forecast for NRx Pharmaceuticals

How were NRx Pharmaceuticals' earnings last quarter?

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) released its quarterly earnings data on Monday, August, 16th. The company reported ($6.51) earnings per share for the quarter.
View NRx Pharmaceuticals' earnings history

Who are NRx Pharmaceuticals' key executives?

NRx Pharmaceuticals' management team includes the following people:
  • Jonathan C. Javitt, Chairman & Chief Executive Officer
  • Robert Besthof, Head-Operations
  • Alessandra Daigneault, Secretary, Treasurer & General Counsel

What is NRx Pharmaceuticals' stock symbol?

NRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "NRXP."

Who are NRx Pharmaceuticals' major shareholders?

NRx Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (1.33%), Linden Advisors LP (0.76%), Owl Creek Asset Management L.P. (0.63%), Northern Trust Corp (0.27%), Morgan Stanley (0.08%) and Morgan Stanley (0.08%).

Which major investors are buying NRx Pharmaceuticals stock?

NRXP stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Linden Advisors LP, Owl Creek Asset Management L.P., Northern Trust Corp, Morgan Stanley, Morgan Stanley, Ionic Capital Management LLC, and Geode Capital Management LLC.

How do I buy shares of NRx Pharmaceuticals?

Shares of NRXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NRx Pharmaceuticals' stock price today?

One share of NRXP stock can currently be purchased for approximately $9.42.

How much money does NRx Pharmaceuticals make?

NRx Pharmaceuticals has a market capitalization of $506.55 million.

How many employees does NRx Pharmaceuticals have?

NRx Pharmaceuticals employs 2 workers across the globe.

What is NRx Pharmaceuticals' official website?

The official website for NRx Pharmaceuticals is www.bigrockpartners.com.

Where are NRx Pharmaceuticals' headquarters?

NRx Pharmaceuticals is headquartered at 2645 N. Federal Highway Suite 230, Delray Beach FL, 33483.

How can I contact NRx Pharmaceuticals?

NRx Pharmaceuticals' mailing address is 2645 N. Federal Highway Suite 230, Delray Beach FL, 33483. The company can be reached via phone at (484) 254-6134.

This page was last updated on 9/27/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.